J. Choi

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

N. Schultz, M. Ladanyi, D. Zelterman, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

R. Herbst, D. Zelterman, D. Rimm, 2018, Nature Communications.

Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer

K. Park, S. Jang, R. Bayliss, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

R. Herbst, D. Zelterman, D. Rimm, 2018, Nature Communications.

IPI59: An Actionable Biomarker to Improve Treatment Response in Serous Ovarian Carcinoma Patients

C. Kendziorski, J. Rader, K. Korthauer, 2017, Statistics in biosciences.

IPI59: An Actionable Biomarker to Improve Treatment Response in Serous Ovarian Carcinoma Patients

J. Rader, K. Eng, W. Bradley, 2017, Statistics in Biosciences.

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutations.

S. Jang, C. Suh, J. Lee, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Specific cell targeting for delivery of toxins into small-cell lung cancer using a streptavidin fusion protein complex.

W. Rom, D. Meruelo, B. Levin, 2000, DNA and cell biology.